AU2018388657C1 - Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors - Google Patents

Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors Download PDF

Info

Publication number
AU2018388657C1
AU2018388657C1 AU2018388657A AU2018388657A AU2018388657C1 AU 2018388657 C1 AU2018388657 C1 AU 2018388657C1 AU 2018388657 A AU2018388657 A AU 2018388657A AU 2018388657 A AU2018388657 A AU 2018388657A AU 2018388657 C1 AU2018388657 C1 AU 2018388657C1
Authority
AU
Australia
Prior art keywords
inhibitors
group
alkyl
antagonists
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018388657A
Other languages
English (en)
Other versions
AU2018388657A1 (en
AU2018388657B2 (en
Inventor
Pingchen Fan
Christopher W. Lange
Rebecca M. LUI
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Rajinder Singh
Yibin Zeng
Penglie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2018388657A1 publication Critical patent/AU2018388657A1/en
Application granted granted Critical
Publication of AU2018388657B2 publication Critical patent/AU2018388657B2/en
Publication of AU2018388657C1 publication Critical patent/AU2018388657C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
AU2018388657A 2017-12-22 2018-12-20 Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors Active AU2018388657C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609844P 2017-12-22 2017-12-22
US62/609,844 2017-12-22
PCT/US2018/066677 WO2019126431A1 (en) 2017-12-22 2018-12-20 DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS

Publications (3)

Publication Number Publication Date
AU2018388657A1 AU2018388657A1 (en) 2020-07-09
AU2018388657B2 AU2018388657B2 (en) 2022-12-01
AU2018388657C1 true AU2018388657C1 (en) 2023-03-23

Family

ID=66950014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018388657A Active AU2018388657C1 (en) 2017-12-22 2018-12-20 Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors

Country Status (15)

Country Link
US (2) US10759807B2 (zh)
EP (1) EP3728202A4 (zh)
JP (1) JP7253557B2 (zh)
KR (1) KR20200110656A (zh)
CN (1) CN111788184B (zh)
AU (1) AU2018388657C1 (zh)
BR (1) BR112020012374A2 (zh)
CA (1) CA3086111A1 (zh)
IL (1) IL275516B2 (zh)
MA (1) MA51327A (zh)
MX (1) MX2020006460A (zh)
NZ (1) NZ765590A (zh)
SG (1) SG11202005799XA (zh)
TW (1) TWI817968B (zh)
WO (1) WO2019126431A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
CN111032658B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的5-5稠合环类
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
CA3086111A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
US10828285B2 (en) * 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
US20190300526A1 (en) * 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
WO2021020363A1 (ja) * 2019-07-29 2021-02-04 武田薬品工業株式会社 複素環化合物
EP4094765A1 (en) 2019-12-19 2022-11-30 Active Biotech AB Compounds for treatment of eye diseases associated with excessive vascularisation
US20230165838A1 (en) * 2020-05-06 2023-06-01 Dimerix Bioscience Ltd. Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
CA3175602A1 (en) * 2020-05-07 2021-11-11 Jerome Molette Novel compounds for diagnosis
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
WO2022093971A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
KR20230149402A (ko) * 2022-04-20 2023-10-27 목포대학교산학협력단 판막 석회화 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214855A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05405B1 (et) 2000-08-10 2011-04-15 Pharmacia Italia S.P.A. Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
JP4196678B2 (ja) 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003082828A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
EP1565452B1 (en) 2002-11-08 2012-04-04 Novartis International Pharmaceutical Ltd. 3-substituted-6-aryl pyridines as ligands of c5a receptors
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) * 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
CN101318962A (zh) * 2003-09-17 2008-12-10 詹森药业有限公司 稠合杂环化合物
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
EP2585064B1 (en) 2010-06-24 2017-05-03 ChemoCentryx, Inc. C5ar antagonists
GB201016880D0 (en) * 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
WO2014028805A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
CN111032658B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的5-5稠合环类
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
CA3086111A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
US20190300526A1 (en) 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214855A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
KR20200110656A (ko) 2020-09-24
JP2021506900A (ja) 2021-02-22
AU2018388657A1 (en) 2020-07-09
US20190194208A1 (en) 2019-06-27
MX2020006460A (es) 2020-11-06
EP3728202A4 (en) 2021-05-26
CN111788184A (zh) 2020-10-16
IL275516B2 (en) 2023-12-01
MA51327A (fr) 2021-05-26
IL275516A (en) 2020-08-31
US11485737B2 (en) 2022-11-01
CN111788184B (zh) 2023-12-22
RU2020124094A (ru) 2022-01-24
WO2019126431A1 (en) 2019-06-27
US20210009596A1 (en) 2021-01-14
NZ765590A (en) 2024-01-26
IL275516B1 (en) 2023-08-01
CA3086111A1 (en) 2019-06-27
BR112020012374A2 (pt) 2020-11-24
EP3728202A1 (en) 2020-10-28
AU2018388657B2 (en) 2022-12-01
SG11202005799XA (en) 2020-07-29
TWI817968B (zh) 2023-10-11
TW201934552A (zh) 2019-09-01
US10759807B2 (en) 2020-09-01
JP7253557B2 (ja) 2023-04-06

Similar Documents

Publication Publication Date Title
AU2018388657B2 (en) Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
AU2018388655B2 (en) Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
US11608336B2 (en) Prodrugs of fused-bicyclic C5aR antagonists
AU2018277523B2 (en) 5-5 fused rings as C5a inhibitors
RU2785549C2 (ru) ДИАРИЛ-ЗАМЕЩЕННЫЕ 5,5 СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR
RU2796983C2 (ru) ДИАРИЛ-ЗАМЕЩЕННЫЕ 6,5-СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR
RU2794327C2 (ru) ПРОЛЕКАРСТВА СОПРЯЖЕННО-БИЦИКЛИЧЕСКИХ АНТАГОНИСТОВ C5aR

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 DEC 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 06 DEC 2022

FGA Letters patent sealed or granted (standard patent)